New phase 3 data test PP-01 to ease cannabis withdrawal, pairing medication with behavioral therapy for moderate-to-severe cannabis use disorder.
Shelli Graham, PhD
Advertisement
Articles by Shelli Graham, PhD
A fast-tracked once-daily pill aims to ease cannabis withdrawal by restoring CB1 signaling and reward-pathway balance as phase 3 enrollment surges.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
3
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
4
First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance
5